Your link actually demonstrates that the US may get there first. You linked a large scale clinical study in the US, whereas OP’s article is a single case study. Also, OP’s case study treated type 2 DM and explicitly noted that Type 1 will be more difficult to treat, while the study you linked is already targeting Type 1. Interested to see how the study you linked turns out!
Just because China got there first doesn’t mean American companies aren’t trying.
https://www.vrtx.com/our-science/pipeline/type-1-diabetes/
… Even after the gutting of the funding?
Look at their share prices
Your link actually demonstrates that the US may get there first. You linked a large scale clinical study in the US, whereas OP’s article is a single case study. Also, OP’s case study treated type 2 DM and explicitly noted that Type 1 will be more difficult to treat, while the study you linked is already targeting Type 1. Interested to see how the study you linked turns out!
Ah, that’ll teach me for not reading the OP link
Sure…
Curing patients is not a sustainable business model.